Download PDF
Semin Thromb Hemost 2006; 32(7): 716-723
DOI: 10.1055/s-2006-951456
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Hyperhomocysteinemia and Venous Thromboembolism

Marco Cattaneo1
  • 1Hematology and Thrombosis Unit, Hospital San Paolo, University of Milan, Milan, Italy
Further Information

Publication History

Publication Date:
06 October 2006 (online)

    Permissions and Reprints

ABSTRACT

Homocysteine (Hcy) is a sulfhydryl amino acid derived from the metabolic conversion of methionine, which is dependent on vitamins (folic acid, B12 and B6) as cofactors or cosubstrates. Severe hyperhomocysteinemia (homocystinuria), due to inherited metabolic defects of Hcy metabolism, is associated with very high risk of venous thromboembolism (VTE); treatment with vitamins is associated with dramatic decrease of VTE risk. Several case-control and prospective studies showed that also mild/moderate hyperhomocysteinemia (which is caused by the interaction of environmental factors with mild genetic abnormalities of Hcy metabolism) is associated with heightened risk of VTE; however, it is uncertain whether treatment with vitamins also decreases the VTE risk in these patients.

KEYWORDS

Venous thrombosis - pulmonary embolism - hyperhomocysteinemia - homocystinuria - folate

REFERENCES

  • 1 Refsum H, Smith A D, Ueland P M et al.. Facts and recommendations about total homocysteine determinations: an expert opinion.  Clin Chem. 2004;  50 3-32
    CrossrefPubMedGoogle Scholar
  • 2 Finkelstein J D. Methionine metabolism in mammals.  J Nutr Biochem. 1990;  1 228-257
    PubMedGoogle Scholar
  • 3 Jacques P F, Bostom A G, Wilson P W, Rich S, Rosenberg I H, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort.  Am J Clin Nutr. 2001;  73 613-621
    PubMedGoogle Scholar
  • 4 Nygård O, Refsum H, Ueland P M, Vollset S E. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study.  Am J Clin Nutr. 1998;  67 263-270
    PubMedGoogle Scholar
  • 5 Mezzano D, Munoz X, Martinez C et al.. Vegetarians and cardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine.  Thromb Haemost. 1999;  81 913-917
    PubMedGoogle Scholar
  • 6 Mann N J, Li D, Sinclair A J et al.. The effect of diet on plasma homocysteine concentrations in healthy male subjects.  Eur J Clin Nutr. 1999;  53 895-899
    CrossrefPubMedGoogle Scholar
  • 7 van Asselt D Z, de Groot L C, van Staveren W A. Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects.  Am J Clin Nutr. 1998;  68 328-334
    PubMedGoogle Scholar
  • 8 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis.  Thromb Haemost. 1999;  81 165-176
    PubMedGoogle Scholar
  • 9 Mudd S H, Levy H L, Skovby F. Disorders of transulfuration. In: Scriver CR, Beaudet AL, Sly WS, et al The Metabolic and Molecular Bases of Inherited Disease. New York; McGraw-Hill 1995: 1279-1327
    Google Scholar
  • 10 Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency.  J Inherit Metab Dis. 1996;  19 589-594
    CrossrefPubMedGoogle Scholar
  • 11 Kang S-S, Zhou J, Wong P WK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a termolabile variant of methylenetetrahydrofolate reductase.  Am J Hum Genet. 1988;  43 414-421
    PubMedGoogle Scholar
  • 12 Frosst P, Blom H J, Milos R et al.. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.  Nat Genet. 1995;  10 111-113
    CrossrefPubMedGoogle Scholar
  • 13 Kluijtmans L A, Young I S, Boreham C A. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.  Blood. 2003;  101 2483-2488
    CrossrefPubMedGoogle Scholar
  • 14 Souto J C, Almasy L, Borrell M. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.  Am J Hum Genet. 2000;  67 1452-1459
    CrossrefPubMedGoogle Scholar
  • 15 Jee S H, Song K S, Shim W H. Major gene evidence after MTHFR-segregation analysis of serum homocysteine in families of patients undergoing coronary arteriography.  Hum Genet. 2002;  111 128-135
    PubMedGoogle Scholar
  • 16 Ueland P M, Refsum H, Stabler S P, Malinow R M, Andersson A, Allen R H. Total homocysteine in plasma or serum. Methods and clinical implications.  Clin Chem. 1993;  39 1764-1779
    PubMedGoogle Scholar
  • 17 Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci P M, Cattaneo M. Multicenter study of homocysteine measurement. Performance characteristics of different methods, influence of standards on interlaboratory agreement of results.  Thromb Haemost. 2001;  85 291-295
    PubMedGoogle Scholar
  • 18 Pfeiffer C M, Huff D L, Smith S J, Miller D T, Gunter E W. Comparison of plasma total homocysteine measurements in 14 laboratories: an international study.  Clin Chem. 1999;  45 1261-1268
    PubMedGoogle Scholar
  • 19 Hanson N Q, Eckfeldt J H, Schwinchtenberg K, Aras Ö, Tsai M Y. Interlaboratory variation of plasma total homocysteine measurements: results of three successive homocysteine proficiency testing surveys.  Clin Chem. 2002;  48 1539-1545
    PubMedGoogle Scholar
  • 20 Fowler B, Sardharwalla I B, Robins A J. The detection of heterozygotes for homocystinuria by oral loading with L-methionine.  Biochem J. 1971;  122 23-24
    PubMedGoogle Scholar
  • 21 Boers G HJ, Fowler B, Smals A GH et al.. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts.  Hum Genet. 1985;  69 164-169
    PubMedGoogle Scholar
  • 22 Falcon C R, Cattaneo M, Panzeri D, Martinelli I, Mannucci P M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.  Arterioscler Thromb. 1994;  14 1080-1083
    PubMedGoogle Scholar
  • 23 Fermo I, Viganò-D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.  Ann Intern Med. 1995;  123 747-753
    PubMedGoogle Scholar
  • 24 Cattaneo M, Martinelli I, Mannucci P M. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.  N Engl J Med. 1996;  335 974-975
    CrossrefPubMedGoogle Scholar
  • 25 Graham I M, Daly L E, Refsum H M et al.. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.  JAMA. 1997;  277 1775-1781
    CrossrefPubMedGoogle Scholar
  • 26 Ubbink J B, Becker P J, Vermaak W J, Delport R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine.  Clin Chem. 1995;  41 1033-1037
    PubMedGoogle Scholar
  • 27 Mandel H, Brenner B, Berant M et al.. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis.  N Engl J Med. 1996;  334 763-768
    CrossrefPubMedGoogle Scholar
  • 28 Quere I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria and factor V Leiden-effects on thrombosis.  N Engl J Med. 1996;  335 289
    CrossrefPubMedGoogle Scholar
  • 29 Kluijtmans L AJ, Boers G HJ, Verbruggen B, Trijbels F JM, Novakova I RO, Blom H J. Homozygous cystathionine β-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis.  Blood. 1998;  91 2015-2018
    PubMedGoogle Scholar
  • 30 Yap S, O'Donnell K A, O'Neill C, Mayne P D, Thornton P, Naughten E. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.  Thromb Haemost. 1999;  81 502-505
    PubMedGoogle Scholar
  • 31 Brattström L, Tangborn L, Lagerstedt C, Israelsson B, Hultber B. Plasma homocysteine in venous thromboembolism.  Haemostasis. 1991;  21 51-57
    PubMedGoogle Scholar
  • 32 Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis: relation to coagulation and fibrinolytic parameters.  Thromb Res. 1993;  70 123-129
    CrossrefPubMedGoogle Scholar
  • 33 den Heijer M, Rosendaal F R, Blom H J, Gerrits W BJ, Bos G MJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis.  Thromb Haemost. 1998;  80 874-877
    PubMedGoogle Scholar
  • 34 Ray J G. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease.  Arch Intern Med. 1998;  158 2101-2106
    CrossrefPubMedGoogle Scholar
  • 35 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies.  J Thromb Haemost. 2005;  3 292-299
    CrossrefPubMedGoogle Scholar
  • 36 Martinelli I, Battaglioli P, Pedotti P, Cattaneo M, Mannucci P M. Hyper-homocysteinemia and cerebral vein thrombosis.  Blood. 2003;  102 1363-1366
    CrossrefPubMedGoogle Scholar
  • 37 Marcucci R, Bertini L, Giusti B et al.. Thrombophilic risk factors in patients with central retinal vein occlusion.  Thromb Haemost. 2001;  86 772-776
    PubMedGoogle Scholar
  • 38 Cahill M T, Stinnett S S, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease.  Am J Ophthalmol. 2003;  136 1136-1150
    CrossrefPubMedGoogle Scholar
  • 39 Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci P M. Risk factors for primary deep vein thrombosis of the upper extremities.  Ann Intern Med. 1997;  126 707-711
    PubMedGoogle Scholar
  • 40 Ridker P M, Hennekens C H, Selhub J, Miletich J P, Malinow M R, Stampfer M J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.  Circulation. 1997;  95 1777-1782
    CrossrefPubMedGoogle Scholar
  • 41 Cattaneo M, Zighetti M L, Turner R M. et al and the ECAT DVT Study Group . Fasting plasma homocysteine levels do not predict the occurrence of deep-vein thrombosis after elective hip replacement surgery.  Neth J Med. 1998;  52(suppl) S21
    PubMedGoogle Scholar
  • 42 Tsai A W, Cushman M, Tsai M Y et al.. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE).  Am J Hematol. 2003;  72 192-200
    CrossrefPubMedGoogle Scholar
  • 43 Eichinger S, Stümpfen A, Hirschl M et al.. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.  Thromb Haemost. 1998;  80 566-569
    PubMedGoogle Scholar
  • 44 Keijzer M B, den Heijer M, Blom H J et al.. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis.  Thromb Haemost. 2002;  88 723-728
    PubMedGoogle Scholar
  • 45 Wald D S, Law M, Morris J K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.  BMJ. 2002;  325 1202-1206
    CrossrefPubMedGoogle Scholar
  • 46 Ray J G, Shmorgun D, Chan W S. Common C677T polymorphism of the methylenetetrahydrofolate gene and the risk of venous thromboembolism. Meta-analysis of 31 studies.  Pathophysiol Haemost Thromb. 2002;  32 51-58
    CrossrefPubMedGoogle Scholar
  • 47 Frederiksen J, Juul K, Grande P et al.. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study.  Blood. 2004;  104 3046-3051
    CrossrefPubMedGoogle Scholar
  • 48 Cattaneo M, Tsai M Y, Bucciarelli P et al.. A common mutation in the methylene-tetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506).  Arterioscler Thromb Vasc Biol. 1997;  17 1662-1666
    PubMedGoogle Scholar
  • 49 Cattaneo M, Chantarangkul V, Taioli E, Hermida Santos J, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels.  Thromb Res. 1999;  93 1-8
    CrossrefPubMedGoogle Scholar
  • 50 Margaglione M, D'Andrea G, d'Addedda M et al.. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the factor V Leiden and the prothrombin A20210 mutation.  Thromb Haemost. 1998;  79 907-911
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Salomon O, Steinberg D M, Zivelin A et al.. Single and combined prothrombotic factors in patients with idiiopathic venous thromboembolism: prevalence and risk assessment.  Arterioscler Thromb Vasc Biol. 1999;  19 511-518
    PubMedGoogle Scholar
  • 52 Akar N, Akar E, Akcay R, Avcu F, Yalcin A, Cin S. Effect of methylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients.  Thromb Res. 2000;  97 163-167
    CrossrefPubMedGoogle Scholar
  • 53 Alhenc-Gelas M, Arnaud E, Nicaud V et al.. Venous thromboembolic disease and the prothrombin, methylenetetrahydrolfolate reductase and factor V genes.  Thromb Haemost. 1999;  81 506-510
    PubMedGoogle Scholar
  • 54 Kluijtmans L AJ, den Heijer M, Reitsma P H, Heil S G, Blom H J, Rosendaal F R. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis.  Thromb Haemost. 1998;  79 254-258
    PubMedGoogle Scholar
  • 55 Brown K, Luddington R, Baglin T. Effect of the MTHFR C677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations.  Br J Haematol. 1998;  103 42-44
    CrossrefPubMedGoogle Scholar
  • 56 De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism.  Semin Thromb Hemost. 2000;  26 305-311
    PubMedGoogle Scholar
  • 57 Epstein F H. The epidemiology of coronary heart disease: a review.  J Chronic Dis. 1965;  18 735-774
    CrossrefPubMedGoogle Scholar
  • 58 Wilhelmsen L, Wedel H, Tibbins G. Multivariate analysis of risk factors for coronary heart disease.  Circulation. 1973;  48 950-958
    PubMedGoogle Scholar
  • 59 Rabkin S W, Sackett D L. Arterial thromboembolism. Epidemiology. In: Colman RW, Hirsh J, Marder VJ, Salzman EW Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia; J.B. Lippincott 1987: 1273-1289
    Google Scholar
  • 60 Yap S, Boers G H, Wilcken B et al.. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study.  Arterioscler Thromb Vasc Biol. 2001;  21 2080-2085
    CrossrefPubMedGoogle Scholar
  • 61 Quere I, Perneger T V, Zittoun J et al.. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study.  Lancet. 2002;  359 747-752
    CrossrefPubMedGoogle Scholar
  • 62 Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci P M. Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis.  Circulation. 2001;  104 2442-2446
    PubMedGoogle Scholar
  • 63 Ubbink J B, Vermaak W JH, van der Merwe A, Becker P J, Delport R, Potgeieter H C. Vitamin requirements for the treatment of hyperhomocysteinemia in humans.  J Nutr. 1994;  124 1927-1933
    PubMedGoogle Scholar
  • 64 den Heijer M, Brower I A, Bos G M et al.. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers.  Arterioscler Thromb Vasc Biol. 1998;  18 356-361
    PubMedGoogle Scholar
  • 65 Homocysteine Lowering Trialists' Collaboration . Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials.  BMJ. 1998;  316 894-898
    PubMedGoogle Scholar
  • 66 Hansson P O, Werlin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population.  Arch Intern Med. 1997;  157 1665-1670
    CrossrefPubMedGoogle Scholar
  • 67 Heit J A, Silverstein M D, Mohr D N et al.. The epidemiology of venous thromboembolism in the community.  Thromb Haemost. 2001;  86 452-463
    PubMedGoogle Scholar
  • 68 Den Heijer M, Willems H PJ, Blom H J et al.. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomized, placebo-controlled, double blind trial.  Blood. 2006;  , In press
    PubMedGoogle Scholar
  • 69 Cattaneo M. Hyperhomocysteinemia: an important risk factor for cardiovascular disease? Potentially, yes.  J Thromb Haemost. 2003;  1 1878-1879
    CrossrefPubMedGoogle Scholar

 Prof.
M. CattaneoM.D. 

Unità di Ematologia e Trombosi, Ospedale San Paolo - Università di Milano, Via di Rudinì

8, 20142 Milano, Italy

Email: marco.cattaneo@unimi.it

      >